Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • Posters & Publications
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jul 14, 2015 7:35am EDT

Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015

Jul 07, 2015 7:35am EDT

Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference

Jun 15, 2015 7:05am EDT

Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)

Jun 10, 2015 7:35am EDT

Matinas BioPharma to Present at the BIO International Convention on June 18, 2015

Jun 04, 2015 7:05am EDT

Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions

Jun 01, 2015 8:00am EDT

Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)

May 28, 2015 7:05am EDT

Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015

May 26, 2015 7:35am EDT

Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015

Apr 10, 2015 12:20pm EDT

Matinas BioPharma Completes Private Placement of $10 Million

Apr 07, 2015 8:05am EDT

Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015

RSS
  • Prev
    • 1...
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • Posters & Publications

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2025 Matinas BioPharma Holdings, Inc. All Rights Reserved.